SLDB Solid Biosciences Inc.

NASDAQ
$6.59

Solid Biosciences Inc. (SLDB) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is a loss of $0.37 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.2% since its last earnings release on November 4, 2026.

Solid Biosciences Beat Consensus Estimates
Wednesday, November 4, 2026 · 4:07 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.37)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $6.38

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Solid Biosciences Inc.

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.